Lilly and AC Immune Announce License and Collaboration Agreement
- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.
- AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commercial milestones, and low double-digit royalties.
- Lilly to purchase $50 million note, convertible to equity position in AC Immune.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ac-immune-announce-license-and-collaboration-agreement-300763835.html
SOURCE Eli Lilly and Company